Andrew Callos, Cytokinetics INC's Executive Vice President and Chief Commercial Officer, completed a pair of stock transactions on March 5, 2026, that combined a sale of existing shares with the exercise of employee options.
Callos sold a total of 26,000 shares of Cytokinetics common stock in two tranches on that date, generating about $1.6 million. The sales were executed at prices ranging narrowly from $61.87 to $61.88 per share. As of the time referenced, Cytokinetics stock is trading at $62.19, a level that represents a 44% increase over the past 12 months; however, InvestingPro’s valuation model places a Fair Value for the shares at $71.12.
On the same day he sold shares, Callos also exercised options to acquire 26,000 shares in two separate option grants. Under those exercises he took 11,000 shares at an exercise price of $39.13 and 15,000 shares at an exercise price of $23.26. The aggregate cash required to execute those option grants amounted to $779,330.
After accounting for the sale and the option exercises, Callos’s directly held position in Cytokinetics stands at 50,440 shares.
On the company fundamentals front, Cytokinetics remains unprofitable, reporting an earnings per share (EPS) of -$6.54. Nonetheless, the analyst community maintains a generally bullish stance on the stock, with published price targets spanning from $61 to $136.
Analyst reactions to Cytokinetics’ recent fourth-quarter results and the commercial introduction of Myqorzo have resulted in a range of updates from the sell-side:
- BofA Securities described the fourth-quarter results as largely uneventful, left a Neutral rating in place and modestly increased its price target to $67.
- Needham maintained a Buy rating and raised its price target to $85, noting that it will require a few quarters to fully assess the early performance of the Myqorzo launch.
- Citizens increased its price target to $96, labeling Cytokinetics a top pick ahead of upcoming results and retaining a Market Outperform rating.
- B. Riley reiterated a Buy rating with a $108 price target and emphasized Myqorzo’s potential to capture market share within the cardiac myosin inhibitor class.
- Barclays initiated coverage with an Overweight rating and a $87 price target, highlighting Myqorzo’s differentiated label and lower monitoring requirements as notable attributes.
These analyst updates come as Cytokinetics navigates a competitive landscape where Bristol Myers Squibb’s Camzyos already displays meaningful market penetration. Observers and sell-side analysts are watching the next several quarters to evaluate how Myqorzo performs against established competitors.
The transactions carried out by Callos - the simultaneous sale and exercise of options - are factual events that change his direct ownership level but do not, on their own, alter Cytokinetics’ financial position or operational trajectory. The company’s near-term outlook will be informed by forthcoming commercial data on Myqorzo, ongoing quarterly results, and competitive dynamics in the cardiac myosin inhibitor market.